Middle-aged adults with positive plasma biomarkers for Alzheimer disease show accelerated decline in specific cognitive domains.

Plasma biomarker analysis took place from 2024 to 2025, with data analysis completed between July 2025 and February 2026.

The SPEAR UltraDetect ™ Parallel Plex Solution enables simultaneous biomarker detection without sacrificing analytical performance. The parallel plex approach, which leverages the platform's low ...

In a recent editorial published in Current Pharmaceutical Analysis (Volume 18, Issue 6, 2022), researchers Dr. Behrouz Seyfinejad and Dr. Abolghasem Jouyban highlight the importance of method ...

Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...

First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research ...

To improve ovarian cancer screening, researchers led by Johns Hopkins University’s Victor E. Velculescu, MD, PhD, developed a combination liquid biopsy approach. It has three components: measurements ...

Researchers from the EHU-University of the Basque Country have developed a robust protocol to detect the molecules involved ...

Cognitive decline in very old adults has been considered for decades to be an almost inevitable consequence of aging. In clinical practice, this has contributed to many memory problems in patients ...

This listicle explores how advanced ICP-MS methods improve sensitivity, streamline multi-element analysis, and strengthen ...